AGEN Earnings Date: Nov 5, 2026 (Estimated) — Agenus Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AGEN's next earnings date?
Agenus Inc. (AGEN) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.02 on revenue of $28.2M.
How did AGEN do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Agenus Inc. posted EPS of -$0.01 versus the $0.04 estimate, a miss of 95.5%. Revenue was $34.5M against a $34.0M estimate. The stock's 1-day post-earnings move was -3.7%.
How much does AGEN stock move after earnings?
AGEN beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.2% (up or down) in the day after earnings.
About Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.04 | -0.01 | +95.48% | $34.5M | ❌ Miss | -3.73% | -11.31% | +5.91% |
| 2026-05-11 | Q1 2026 | 1.83 | 1.02 | -44.26% | $33.7M | ❌ Miss | -14.66% | -6.28% | -18.59% |
| 2026-03-16 | Q4 2025 | -1.28 | -0.37 | +71.09% | $34.2M | ✅ Beat | +6.13% | +19.68% | +52.26% |
| 2025-11-10 | Q3 2025 | 2.24 | 1.94 | -13.39% | $30.2M | ❌ Miss | +5.78% | +9.05% | -1.51% |
| 2025-08-11 | Q2 2025 | 0.50 | -1.00 | -300.00% | $25.7M | ❌ Miss | -11.04% | -3.54% | +5.63% |
| 2025-03-11 | Q4 2024 | -2.54 | -2.04 | +19.69% | $26.8M | ✅ Beat | -4.65% | -17.21% | -20.93% |
| 2024-11-12 | Q3 2024 | -2.33 | -3.08 | -32.19% | $25.1M | ❌ Miss | -20.38% | -32.56% | -16.15% |
| 2024-05-07 | Q1 2024 | -2.83 | -3.04 | -7.42% | $28.0M | ❌ Miss | -7.26% | -14.36% | +35.68% |
Showing last 8 quarters.